Author:
Lindhoff-Last Edelgard,Samama Meyer Michel,Ortel Thomas L,Weitz Jeffrey I,Spiro Theodore E
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Pharmacology (medical),Pharmacology
Reference44 articles.
1. Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor.;Roehrig;J Med Chem,2005
2. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor.;Perzborn;J Thromb Haemost,2005
3. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in healthy subjects.;Mueck;Int J Clin Pharmacol Ther,2007
4. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery.;Mueck;Clin Pharmacokinet,2008
5. Monitoring the new antithrombotic drugs.;Walenga;Semin Thromb Hemost,2004
Cited by
146 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献